Novo Nordisk reports Wegovy reduces food‑noise scores in real‑world studies
Novo Nordisk presented data from the SIGNAL and OCTANE real‑world studies at ObesityWeek 2026 showing that semaglutide (Wegovy) lowered self‑reported food‑noise scores. In the OCTANE study, oral semaglutide users saw about a 25% drop in scores after three months, and 86.4% reported at least one treatment improvement. The SIGNAL study of more than 26,000 adults found food‑noise scores fell significantly within the first month of injectable semaglutide and the improvement persisted through six months.
Why it matters
The company says the findings suggest semaglutide may offer benefits beyond weight loss, potentially expanding its appeal to patients concerned with intrusive food thoughts. This could influence prescribing patterns and market perception of Wegovy.
Key facts
- 1The OCTANE study included 7,669 adults who initiated oral semaglutide between 5 Jan and 7 Feb 2026. finance.yahoo.com
- 2In OCTANE, average food‑noise scores fell by ~25% from baseline after three months (from 2.8 to 2.1, p<0.001). finance.yahoo.com
- 386.4% of OCTANE participants reported at least one treatment improvement after three months. finance.yahoo.com
- 4The SIGNAL study analyzed more than 26,000 treatment‑naïve adults with overweight or obesity. rttnews.com
- 5In SIGNAL, food‑noise scores declined significantly within the first month of injectable semaglutide and the greatest improvements were observed during the first three months, remaining through six months. rttnews.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.